公开(公告)号：US20130012412A1

公开(公告)日：2013-01-10

申请号：US13618415

申请日：2012-09-14

申请人： Masahiko KURODA ,  Masami TANAKA ,  Kosuke OIKAWA ,  Takayuki MIZUTANI ,  Masakatsu TAKANASHI

发明人： Masahiko KURODA ,  Masami TANAKA ,  Kosuke OIKAWA ,  Takayuki MIZUTANI ,  Masakatsu TAKANASHI

IPC分类号： C40B30/04

CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  C12Q2600/178

摘要： An embodiment of the present invention provides a marker, a test method, and a test kit which can detect the onset of breast cancer that cannot be detected by palpation or mammography examination or breast cancer in an early stage (clinical stage 0), which are simple, and which have high reliability.A marker associated with breast cancer of an embodiment of the present invention is characterized by being a micro-RNA that is found in serum or plasma. More specifically, the marker contains at least a micro-RNA that is present in the serum or the plasma at a significantly reduced level after the onset of breast cancer, or during or after an early stage (during or after clinical stage 0) of breast cancer compared with that before the onset of breast cancer or before the early stage (before clinical stage 0) of breast cancer.

摘要翻译： 本发明的一个实施方案提供了可以检测在早期阶段（临床阶段0）不能通过触诊或乳房X线照相检查或乳腺癌检测到的乳腺癌发作的标志物，测试方法和测试试剂盒，其为 简单，可靠性高。 与本发明实施方案的乳腺癌相关的标志物的特征在于是在血清或血浆中发现的微RNA。 更具体地，标记物在乳腺癌发作后或在乳腺早期（临床阶段0期间或之后）期间或之后存在于血清或血浆中存在的至少一种微RNA，其显着降低水平 与乳腺癌发病前或乳腺癌早期（临床阶段0之前）癌症相比较。

公开(公告)号：US20140170648A1

公开(公告)日：2014-06-19

申请号：US14039835

申请日：2013-09-27

申请人： Masahiko KURODA ,  Masami TANAKA ,  Kosuke OIKAWA ,  Takayuki MIZUTANI ,  Masakatsu TAKANASHI ,  Seiko IIZUKA ,  Yoshinori KOSUGI ,  Kazuma OHYASHIKI ,  Akihiko TSUCHIDA

发明人： Masahiko KURODA ,  Masami TANAKA ,  Kosuke OIKAWA ,  Takayuki MIZUTANI ,  Masakatsu TAKANASHI ,  Seiko IIZUKA ,  Yoshinori KOSUGI ,  Kazuma OHYASHIKI ,  Akihiko TSUCHIDA

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/178

摘要： The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.

摘要翻译： 本发明提供了用于评估受试者的癌症的发病，临床前期，临床阶段或预后的新型癌症标志物及其评价方法。 使用含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA的癌症标记物作为不包括乳腺癌的癌症的标志物。 用于评估除乳腺癌之外的癌症的可能性的方法包括检测从受试者收集的生物样品中癌症标志物的表达水平的步骤。 在该方法中，癌标记物含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA。

公开(公告)号：US08632967B2

公开(公告)日：2014-01-21

申请号：US13472190

申请日：2012-05-15

申请人： Masahiko Kuroda ,  Masami Tanaka ,  Kosuke Oikawa ,  Takayuki Mizutani ,  Masakatsu Takanashi ,  Seiko Iizuka ,  Yoshinori Kosugi ,  Kazuma Ohyashiki ,  Akihiko Tsuchida

发明人： Masahiko Kuroda ,  Masami Tanaka ,  Kosuke Oikawa ,  Takayuki Mizutani ,  Masakatsu Takanashi ,  Seiko Iizuka ,  Yoshinori Kosugi ,  Kazuma Ohyashiki ,  Akihiko Tsuchida

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/178

摘要： The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.

摘要翻译： 本发明提供了用于评估受试者的癌症的发病，临床前期，临床阶段或预后的新型癌症标志物及其评价方法。 使用含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA的癌症标记物作为不包括乳腺癌的癌症的标志物。 用于评估除乳腺癌之外的癌症的可能性的方法包括检测从受试者收集的生物样品中癌症标志物的表达水平的步骤。 在该方法中，癌标记物含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA。

公开(公告)号：US08828964B2

公开(公告)日：2014-09-09

申请号：US13613626

申请日：2012-09-13

申请人： Masahiko Kuroda ,  Masakatsu Takanashi ,  Kosuke Oikawa

发明人： Masahiko Kuroda ,  Masakatsu Takanashi ,  Kosuke Oikawa

IPC分类号： C12N15/113 ,  C07H21/04

CPC分类号： C12N15/113 ,  A61K31/7088 ,  C12N2310/11 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N33/57496

摘要： Disclosed is an identification marker which can be utilized for detection of various human cancer cells and whose expression closely relates to malignant alteration of cells, and compositions for human cancer treatment which are based on suppression of cancer cell proliferation through inhibition of expression of the identification marker. The marker is human heterochromatin protein 1γ (HP1γ), and the compositions for cancer treatment comprises one or more agents which suppresses the expression of human HP1γ gene, such as siRNAs to human HP1γ.

摘要翻译： 公开了可用于检测各种人类癌细胞并且其表达与细胞的恶性改变密切相关的鉴定标记物，以及基于通过抑制识别标志物表达抑制癌细胞增殖的人类癌症治疗用组合物 。 标记物是人异染色质蛋白1γ（HP1γ），癌症治疗用组合物包含抑制人HP1γ基因（例如人HP1γ的siRNA）表达的一种或多种。

公开(公告)号：US07776525B2

公开(公告)日：2010-08-17

申请号：US10564481

申请日：2004-01-13

申请人： Masahiko Kuroda ,  Kosuke Oikawa ,  Yoshinori Kosugi ,  Tetsuya Ohbayashi

发明人： Masahiko Kuroda ,  Kosuke Oikawa ,  Yoshinori Kosugi ,  Tetsuya Ohbayashi

IPC分类号： C12Q1/68

CPC分类号： G01N33/6893

摘要： The expression level of a histamine-releasing factor (HRF) polynucleotide in a biological sample of a subject is measured and the HRF polynucleotide content is compared with that of a normal biological sample. An HRF polynucleotide expression level considerably higher than that of the normal biological sample is employed as an indication of a disease relating to endometriosis or a risk thereof.

摘要翻译： 测量受试者生物样品中组胺释放因子（HRF）多核苷酸的表达水平，并将HRF多核苷酸含量与正常生物样品的表达水平进行比较。 使用显着高于正常生物样品的HRF多核苷酸表达水平作为与子宫内膜异位症或其风险有关的疾病的指征。

公开(公告)号：US20070184485A1

公开(公告)日：2007-08-09

申请号：US10564484

申请日：2004-01-13

申请人： Yoshinori Kosugi ,  Masahiko Kuroda ,  Kosuke Oikawa ,  Tetsuya Ohbayashi

发明人： Yoshinori Kosugi ,  Masahiko Kuroda ,  Kosuke Oikawa ,  Tetsuya Ohbayashi

IPC分类号： G01N33/53 ,  C07K16/22

CPC分类号： C07K14/52 ,  A61K48/00 ,  C07K16/18 ,  C12N2799/027 ,  G01N33/6863 ,  G01N33/6893

摘要： The level of a histamine-releasing factor (HRF) protein in a biological sample of a subject is measured and the HRF protein level is compared with that of a normal biological sample. A significantly higher HRF protein level compared with that of the normal biological sample is used as an indicator of a disease related to endometriosis or the degree of its risk.

摘要翻译： 测量受试者生物样品中组胺释放因子（HRF）蛋白的水平，并将HRF蛋白水平与正常生物样品的水平进行比较。 与正常生物样品相比，显着更高的HRF蛋白水平被用作与子宫内膜异位症或其风险程度相关的疾病的指标。

公开(公告)号：US20070015160A1

公开(公告)日：2007-01-18

申请号：US10564481

申请日：2004-01-13

申请人： Masahiko Kuroda ,  Kosuke Oikawa ,  Yoshinori Kosugi ,  Tetsuya Ohbayashi

发明人： Masahiko Kuroda ,  Kosuke Oikawa ,  Yoshinori Kosugi ,  Tetsuya Ohbayashi

IPC分类号： C12Q1/68 ,  C12P19/34 ,  C07H21/04

CPC分类号： G01N33/6893

摘要： The expression level of a histamine-releasing factor (HRF) polynucleotide in a biological sample of a subject is measured and the HRF polynucleotide content is compared with that of a normal biological sample. An HRF polynucleotide expression level considerably higher than that of the normal biological sample is employed as an indication of a disease relating to endometriosis or a risk thereof.

摘要翻译： 测量受试者生物样品中组胺释放因子（HRF）多核苷酸的表达水平，并将HRF多核苷酸含量与正常生物样品的表达水平进行比较。 使用显着高于正常生物样品的HRF多核苷酸表达水平作为与子宫内膜异位症或其风险有关的疾病的指征。

公开(公告)号：US08592145B2

公开(公告)日：2013-11-26

申请号：US13472190

申请日：2012-05-15

申请人： Masahiko Kuroda ,  Masami Tanaka ,  Kosuke Oikawa ,  Takayuki Mizutani ,  Masakatsu Takanashi ,  Seiko Iizuka ,  Yoshinori Kosugi ,  Kazuma Ohyashiki ,  Akihiko Tsuchida

发明人： Masahiko Kuroda ,  Masami Tanaka ,  Kosuke Oikawa ,  Takayuki Mizutani ,  Masakatsu Takanashi ,  Seiko Iizuka ,  Yoshinori Kosugi ,  Kazuma Ohyashiki ,  Akihiko Tsuchida

IPC分类号： C12Q1/68

摘要： The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.

公开(公告)号：US20120270746A1

公开(公告)日：2012-10-25

申请号：US13472190

申请日：2012-05-15

申请人： Masahiko KURODA ,  Masami Tanaka ,  Kosuke Oikawa ,  Takayuki Mizutani ,  Masakatsu Takanashi ,  Seiko Iizuka ,  Yoshinori Kosugi ,  Kazuma Ohyashiki ,  Akihiko Tsuchida

发明人： Masahiko KURODA ,  Masami Tanaka ,  Kosuke Oikawa ,  Takayuki Mizutani ,  Masakatsu Takanashi ,  Seiko Iizuka ,  Yoshinori Kosugi ,  Kazuma Ohyashiki ,  Akihiko Tsuchida

IPC分类号： C12Q1/68 ,  G01N21/64 ,  C40B30/04

CPC分类号： C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/178

摘要： The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.

摘要翻译： 本发明提供了用于评估受试者的癌症的发病，临床前期，临床阶段或预后的新型癌症标志物及其评价方法。 使用含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA的癌症标记物作为不包括乳腺癌的癌症的标志物。 用于评估除乳腺癌之外的癌症的可能性的方法包括检测从受试者收集的生物样品中癌症标志物的表达水平的步骤。 在该方法中，癌标记物含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA。

公开(公告)号：US20110143360A1

公开(公告)日：2011-06-16

申请号：US12990330

申请日：2009-04-28

申请人： Masahiko Kuroda ,  Masami Tanaka ,  Kosuke Oikawa ,  Takayuki Mizutani ,  Masakatsu Takanashi ,  Seiko Iizuka ,  Yoshinori Kosugi ,  Kazuma Ohyashiki ,  Akihiko Tsuchida

发明人： Masahiko Kuroda ,  Masami Tanaka ,  Kosuke Oikawa ,  Takayuki Mizutani ,  Masakatsu Takanashi ,  Seiko Iizuka ,  Yoshinori Kosugi ,  Kazuma Ohyashiki ,  Akihiko Tsuchida

IPC分类号： C12Q1/68 ,  C07H21/02

CPC分类号： C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/178

摘要： The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.

摘要翻译： 本发明提供了用于评估受试者的癌症的发病，临床前期，临床阶段或预后的新型癌症标志物及其评价方法。 使用含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA的癌症标记物作为不包括乳腺癌的癌症的标志物。 用于评估除乳腺癌之外的癌症的可能性的方法包括检测从受试者收集的生物样品中癌症标志物的表达水平的步骤。 在该方法中，癌标记物含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA。